> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Integra's Tissue Reconstruction Unit Clears Goodwill Test With 11.3% To Spare, A Year After $511.4 Million Write-Off
- URL: https://www.bullished.co/integras-tissue-reconstruction-unit-clears-goodwill-test-with-11-3-to-spare-a-year-after-8581975a/
- Published: 2026-10-23T20:16:34.000Z
- Updated: 2026-10-23T20:16:34.000Z
- Description: Integra's 10-Q shows Neurosurgery has a wider 15.3% cushion, and both units stayed above carrying value in a stress test.
- Author: Matteo Parrino
- Tags: SEC Filings, IART, Industry: Healthcare

[Integra LifeSciences](https://www.bullished.co/tag/iart/), a medical device maker, said in its [10-Q](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000077/iart-20260930.htm?ref=bullished.co) that its Tissue Reconstruction unit passed this year's goodwill test with [11.3% headroom](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000077/iart-20260930.htm?ref=bullished.co), the thinner of its two cushions. Neurosurgery cleared with 15.3%, and the filing came a year after the company wrote off $511.4 million of goodwill.

## Two cushions, one stress test

Goodwill is the premium a company paid for acquired businesses; headroom is how far a unit's estimated fair value sits above its carrying value. Both units were tested at a 13.0% discount rate and 2.5% terminal growth, and neither needed an impairment charge.

The company also ran a hypothetical: raise the discount rate by 50 basis points (half a percentage point) and cut terminal growth by the same amount. That would reduce fair value by 3.8% for Tissue Reconstruction and 3.0% for Neurosurgery. Both would still sit above carrying value, the company said.

Tissue Reconstruction carried $267.8 million of goodwill at September 30, 2026, down from $271.0 million at the end of 2025 on currency translation. Specialty Surgery, which includes Neurosurgery, carried $340.1 million.

## A harder test than last time

This year both units were tested quantitatively, with the company choosing to skip the softer qualitative review. The [prior quarter's filing](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000058/iart-20260630.htm?ref=bullished.co) said last year's third-quarter annual test was qualitative, with no quantitative test needed. The 2025 impairment test used a 13.5% rate.

The Codman tradename, carried at $175.1 million, was also tested quantitatively, at a 14.0% discount rate versus 14.5% in the 2025 test. No impairment was recorded.

## Where the softness sits

Tissue Reconstruction revenue fell 2% to $107.1 million in the third quarter, with lower sales of MicroMatrix and Integra Skin offsetting growth in PriMatrix and DuraSorb. For nine months the segment rose 1% to $325.3 million.

CEO Stuart Essig, in the [earnings release](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000073/ex991-q32026earningsrelease.htm?ref=bullished.co), cited "softer-than-expected results in Tissue Reconstruction" and "more measured expectations for portions of our Tissue Reconstruction business." Specialty Surgery revenue rose 4% to $304.1 million, despite about $7 million lost to the Cincinnati flood.

The company reported third-quarter net income of $14.9 million, against a $5.4 million loss a year earlier. Integra's market value was $959 million at Friday's close.

The company's 10-Q puts the Tissue Reconstruction cushion at 11.3% and says a combined 50-basis-point shift in its two key assumptions would take 3.8% off fair value.

### Sources

- [10-Q Filing — Integra LifeSciences (IART)](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000077/iart-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Integra LifeSciences (IART), Q2 FY2026 filed 2026-07-29 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000058/iart-20260630.htm?ref=bullished.co) — SEC EDGAR
- [8-K Filing — Integra LifeSciences, filed 2026-10-19 (Items 1.01, 1.02, 2.03, 7.01, 9.01)](https://www.sec.gov/Archives/edgar/data/0000917520/000119312526425271/d142199d8k.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, ex991-q32026earningsrelease.htm) — Integra LifeSciences, filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/0000917520/000091752026000073/ex991-q32026earningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [Integra LifeSciences Reports Third Quarter 2026 Financial Results](https://finance.yahoo.com/healthcare/articles/integra-lifesciences-reports-third-quarter-100000903.html?ref=bullished.co) — Yahoo Finance
- [Integra LifeSciences (NASDAQ:IART) Posts Q3 2026 Sales In Line With Estimates But Quarterly Revenue Guidance Misses Expectations](https://finance.yahoo.com/healthcare/articles/integra-lifesciences-nasdaq-iart-posts-101022372.html?ref=bullished.co) — Yahoo Finance
- [Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates](https://finance.yahoo.com/markets/stocks/articles/integra-iart-q3-earnings-taking-123004685.html?ref=bullished.co) — Yahoo Finance
- [Integra outlines $1.634B-$1.654B 2026 revenue outlook as Cincinnati disruption extends into Q2 2027 (NASDAQ:IART)](https://seekingalpha.com/news/4655444-integra-outlines-1%5F634b-1%5F654b-2026-revenue-outlook-as-cincinnati-disruption-extends-into-q2?ref=bullished.co) — seekingalpha.com
- [Integra LifeSciences Q3 earnings beat estimates, but revenue falls short (IART:NASDAQ)](https://seekingalpha.com/news/4655035-integra-lifesciences-q3-earnings-beat-estimates-but-revenue-falls-short?ref=bullished.co) — seekingalpha.com

### More on Integra LifeSciences

- [Integra CEO Expects To 'Lose Some Business' In Neurosurgery As Mayfield Clamp Supply Runs Short Into 2027](https://www.bullished.co/integra-ceo-expects-to-lose-some-business-in-neurosurgery-as-mayfield-clamp-supply-runs-ced12802/)
- [Integra Posts $14.9 Million Profit Against Year-Ago Loss, With Revenue Up 2.3% To $411.2 Million](https://www.bullished.co/integra-posts-14-9-million-profit-against-year-ago-loss-with-revenue-up-2-3-to-411-2-f6cdb83e/)
- [Integra Sells $450 Million Of 9.500% Secured Notes And Rebuilds Its $1.65 Billion Credit Facility](https://www.bullished.co/integra-sells-450-million-of-9-500-secured-notes-and-rebuilds-its-1-65-billion-credit-f9061c2f/)

[All Integra LifeSciences (IART) coverage →](https://www.bullished.co/tag/iart/)